Lung Cancer Therapeutics Market Analysis by Disease Type (Small Cell Lung Cancer (SCLC), Non-Small Cell Lung Cancer (NSCLC), by Treatment (Immunotherapy, Radiation Therapy, Chemotherapy, Targeted Therapy), and by Region - Forecast to 2029

The global lung cancer therapeutics market size is estimated to be USD 24.76 billion in 2021 and is expected to witness a CAGR of 14.71% during the forecast period.  Increasing cases of lung cancer is a key driver for the growth of the global lung cancer therapeutics market. Additionally, rise in pollution attributed to the rapid industrialization, growth in increase of smokers globally, and increase in investment in R&D for new drugs in the market are some of the other drivers propelling the market growth. Nevertheless, growth in side effects of drugs used in treatment and stringent regulatory situation for new product launches are expected to restrain the global market growth.

Global Lung Cancer Therapeutics Market Size (USD Billion), 2021-2029

Source: Erevna Healthcare

By Disease Type

Based on disease type, the market is categorized into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). In 2021, the non-small cell lung cancer (NSCLC) segment accounted for the substantial revenue share with lucrative CAGR during the forecast period. This is due to the fact that this type of cancer is mainly found in regular or former smokers worldwide. The small cell lung cancer (SCLC) segment is anticipated to grow at a profitable CAGR during the forecast period, due the use of chemotherapy and radiation therapy for treatment of these type of cancers are the key factors driving the market worldwide.

By Treatment

Based on treatment, the market is categorized into immunotherapy, radiation therapy, chemotherapy, targeted therapy, and others. In 2021, the chemotherapy segment accounted for the substantial revenue share with lucrative CAGR during the forecast period. This is due to the growing demand for chemotherapy as it is a drug treatment that uses chemicals for killing the fast growing cells in the body, the demand is growing worldwide. The targeted therapy segment is anticipated to grow at a profitable CAGR during the forecast period, due to the application of highly efficient drugs delivery due to targeted therapy.

Regional Insights

In 2021, North America accounted for the highest revenue share in the global market and is expected to maintain its dominance during the forecast period. This is attributed to the growing cases of lung cancer, rising geriatric population, and the shifting standard of living with growing smoking habits in the region. Asia Pacific market is projected to exhibit the fastest CAGR over the forecast period owing to the increase in awareness about improved healthcare, growing government and private sector investment in healthcare industry, increasing aged population, and availability of skilled labor forces at economic costs, are the major factors in this region.

Competitor Insights

Some of the key players in the lung cancer therapeutics  market are AstraZeneca (U.K.); Boehringer Ingelheim (Germany); Bristol-Myers Squibb Company (U.S.); Eli Lilly and Company (U.S.); Genentech, Inc. (U.S.); GlaxoSmithKline plc  (U.K.); F. Hoffmann-La Roche AG (Switzerland); Merck & Co., Inc. (U.S.); Pfizer, Inc. (U.S.); and Ventana Medical Systems, Inc. (U.S.). The leading players operating in the lung cancer therapeutics industry are adopting various strategies including R&D investments, new technology launches, mergers & acquisitions, and regional expansions to capture a maximum revenue share.

This exhaustive research report focuses on market size and forecast at global, segmental, regional and country level along with key market trends and dynamics from 2021 to 2029. The lung cancer therapeutics market report is categorized into the following segments and subsegments.

Lung Cancer Therapeutics Market, By Disease Type (Revenue, USD Billion, 2021 – 2029)

  • Small Cell Lung Cancer (SCLC)
  • Non-Small Cell Lung Cancer (NSCLC)

Lung Cancer Therapeutics Market, By Treatment (Revenue, USD Billion, 2021 – 2029)

  • Immunotherapy
  • Radiation Therapy
  • Chemotherapy
  • Targeted Therapy
  • Others

Lung Cancer Therapeutics Market, By Region (Revenue, USD Billion, 2021 – 2029)

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Spain
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of APAC
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of LATAM
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • Rest of MEA

Scope of Lung Cancer Therapeutics Market Report:

Key Parameters Details
Base Year
  • 2021
Forecast Period
  • 2022-2029
Study Coverage
  • Global and regional market size and revenue forecast
  • Segment market size and revenue forecast at global, regional, and country level
  • Competitive landscape (company share analysis, company profiles, recent development, competitive map analysis)
  • Conclusion and recommendations
Qualitative Analysis
  • Market drivers
  • Market restraints
  • Market opportunities
  • Recent market trends
  • Market challenges
  • Porter’s Five Forces analysis
  • PEST analysis
  • Value-chain analysis
  • COVID-19 impact analysis
Regional Market Scope
  • North America (U.S. and Canada)
  • Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
  • Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
  • Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
  • MEA (South Africa, GCC, Rest of MEA)
Company Profiles
  • Exhaustive profiles of top 15 players
  • 50+ other major players listing
15% Free Customization Available
  • You can customize the study scope to meet your exact requirement. Click here for more details

Table of Contents: Lung Cancer Therapeutics Market 2021-2029

  1. Research Methodology
    1. Study Objectives
    2. Study Scope
    3. Research Assumptions
    4. Research Framework
      1. Research Models
        1. Bottom-up Approach
        2. Top-down Approach
        3. Data Triangulation
      2. Data Procurement
        1. Internal Database
        2. Secondary Research
        3. Purchased Database
        4. Primary Research
      3. Data Analysis
        1. Data Validation
        2. Market Size Estimation
        3. Market Forecast Model
      4. Quality Assessment
  1. Introduction: Lung Cancer Therapeutics
  2. Executive Summary
    1. Global Market Scenario
    2. Segment Market Scenario
    3. Geographic Market Scenario
    4. COVID-19 Impact
    5. Competitive Landscape
  3. Market Dynamics
    1. Market Drivers
      1. Driver 1
      2. Driver 2
      3. Driver 3
      4. Driver 4
      5. Driver 5
    2. Market Restraint
      1. Restraint 1
      2. Restraint 2
      3. Restraint 3
      4. Restraint 4
    3. Market Opportunities
      1. Opportunity 1
      2. Opportunity 2
      3. Opportunity 3
      4. Opportunity 4
    4. Market Trends
      1. Trend 1
      2. Trend 2
      3. Trend 3
      4. Trend 4
    5. Market Challenges
      1. Challenge 1
      2. Challenge 2
      3. Challenge 3
      4. Challenge 4
  1. Market Environment Analysis
    1. Porter’s 5 Forces Analysis
    2. PESTEL Analysis
    3. Value Chain Analysis
    4. SWOT Analysis
    5. Benchmark
  2. COVID-19 Impact Analysis: Lung Cancer Therapeutics Market
    1. COVID-19: Overview
    2. COVID-19 Impact on the Global Market
    3. COVID-19 Impact on the Regional Markets
  3. Market Analysis by Technology
    1. Microscopic Diagnostics
      1. Microscopic Diagnostics Market Forecast, 2021-2029 (USD Million)
    2. Clinical Diagnostics
      1. Clinical Diagnostics Market Forecast, 2021-2029 (USD Million)
    3. Molecular Diagnostics
      1. Molecular Diagnostics Market Forecast, 2021-2029 (USD Million)
    4. Rapid Diagnostic Tests (RDTs)
      1. Rapid Diagnostic Tests (RDTs) Market Forecast, 2021-2029 (USD Million)
    5. Other Technologies
      1. Other Technologies Market Forecast, 2021-2029 (USD Million)
  1. Regional Market Analysis
    1. Regional Market Trends
    2. Regional Market: Comparative Analysis
  2. North America Lung Cancer Therapeutics Market
    1. North America Lung Cancer Therapeutics Market
      1. North America Market Size and Forecast, 2021-2029 (USD Million)
        1. Market Size and Forecast by Technology, 2021-2029 (USD Million)
      2. S. Lung Cancer Therapeutics Market
        1. S. Market Size and Forecast, 2021-2029 (USD Million)
          1. Market Size and Forecast by Technology, 2021-2029 (USD Million)
        2. Canada Lung Cancer Therapeutics Market
          1. Canada Market Size and Forecast, 2021-2029 (USD Million)
            1. Market Size and Forecast by Technology, 2021-2029 (USD Million)
  1. Europe Lung Cancer Therapeutics Market
    1. Europe Lung Cancer Therapeutics Market
      1. Europe Market Size and Forecast, 2021-2029 (USD Million)
        1. Market Size and Forecast by Technology, 2021-2029 (USD Million)
      2. Germany Lung Cancer Therapeutics Market
        1. Germany Market Size and Forecast, 2021-2029 (USD Million)
          1. Market Size and Forecast by Technology, 2021-2029 (USD Million)
        2. UK Lung Cancer Therapeutics Market
          1. UK Market Size and Forecast, 2021-2029 (USD Million)
            1. Market Size and Forecast by Technology, 2021-2029 (USD Million)
          2. France Lung Cancer Therapeutics Market
            1. France Market Size and Forecast, 2021-2029 (USD Million)
              1. Market Size and Forecast by Technology, 2021-2029 (USD Million)
            2. Spain Lung Cancer Therapeutics Market
              1. Spain Market Size and Forecast, 2021-2029 (USD Million)
                1. Market Size and Forecast by Technology, 2021-2029 (USD Million)
              2. Italy Lung Cancer Therapeutics Market
                1. Italy Market Size and Forecast, 2021-2029 (USD Million)
                  1. Market Size and Forecast by Technology, 2021-2029 (USD Million)
                2. Rest of Europe Lung Cancer Therapeutics Market
                  1. Rest of Europe Market Size and Forecast, 2021-2029 (USD Million)
                    1. Market Size and Forecast by Technology, 2021-2029 (USD Million)
  1. Asia Pacific Lung Cancer Therapeutics Market
    1. Asia Pacific Lung Cancer Therapeutics Market
      1. Asia Pacific Market Size and Forecast, 2021-2029 (USD Million)
        1. Market Size and Forecast by Technology, 2021-2029 (USD Million)
      2. Japan Lung Cancer Therapeutics Market
        1. Japan Market Size and Forecast, 2021-2029 (USD Million)
          1. Market Size and Forecast by Technology, 2021-2029 (USD Million)
        2. China Lung Cancer Therapeutics Market
          1. China Market Size and Forecast, 2021-2029 (USD Million)
            1. Market Size and Forecast by Technology, 2021-2029 (USD Million)
          2. India Lung Cancer Therapeutics Market
            1. India Market Size and Forecast, 2021-2029 (USD Million)
              1. Market Size and Forecast by Technology, 2021-2029 (USD Million)
            2. South Korea Lung Cancer Therapeutics Market
              1. South Korea Market Size and Forecast, 2021-2029 (USD Million)
                1. Market Size and Forecast by Technology, 2021-2029 (USD Million)
              2. Australia Lung Cancer Therapeutics Market
                1. Australia Market Size and Forecast, 2021-2029 (USD Million)
              3. Rest of Asia Pacific Lung Cancer Therapeutics Market
                1. Rest of Asia Pacific Market Size and Forecast, 2021-2029 (USD Million)
  1. Latin America Lung Cancer Therapeutics Market
    1. Latin America Lung Cancer Therapeutics Market
      1. Latin America Market Size and Forecast, 2021-2029 (USD Million)
        1. Market Size and Forecast by Technology, 2021-2029 (USD Million)
      2. Brazil Lung Cancer Therapeutics Market
        1. Brazil Market Size and Forecast, 2021-2029 (USD Million)
          1. Market Size and Forecast by Technology, 2021-2029 (USD Million)
        2. Mexico Lung Cancer Therapeutics Market
          1. Mexico Market Size and Forecast, 2021-2029 (USD Million)
            1. Market Size and Forecast by Technology, 2021-2029 (USD Million)
          2. Argentina Lung Cancer Therapeutics Market
            1. Argentina Market Size and Forecast, 2021-2029 (USD Million)
              1. Market Size and Forecast by Technology, 2021-2029 (USD Million)
            2. Rest of Latin America Lung Cancer Therapeutics Market
              1. Rest of Latin America Market Size and Forecast, 2021-2029 (USD Million)
                1. Market Size and Forecast by Technology, 2021-2029 (USD Million)
  1. MEA Lung Cancer Therapeutics Market
    1. MEA Lung Cancer Therapeutics Market
      1. MEA Market Size and Forecast, 2021-2029 (USD Million)
        1. Market Size and Forecast by Technology, 2021-2029 (USD Million)
      2. GCC Lung Cancer Therapeutics Market
        1. GCC Market Size and Forecast, 2021-2029 (USD Million)
          1. Market Size and Forecast by Technology, 2021-2029 (USD Million)
        2. South Africa Lung Cancer Therapeutics Market
          1. South Africa Market Size and Forecast, 2021-2029 (USD Million)
            1. Market Size and Forecast by Technology, 2021-2029 (USD Million)
          2. Rest of MEA Lung Cancer Therapeutics Market
            1. Rest of MEA Market Size and Forecast, 2021-2029 (USD Million)
              1. Market Size and Forecast by Technology, 2021-2029 (USD Million)
  1. Competitor Analysis
    1. Market Share Analysis, 2021 & 2029
    2. Competitive Mapping
    3. Key Players Market Place Analysis
    4. Major Recent Developments
  2. Company Profiles
    1. AstraZeneca (U.K.)
      1. Company Snapshot
      2. Company Overview
      3. Financials
      4. Technology Benchmarking
      5. Recent Developments
    2. Boehringer Ingelheim (Germany)
      1. Company Snapshot
      2. Company Overview
      3. Financials
      4. Technology Benchmarking
      5. Recent Developments
    3. Bristol-Myers Squibb Company (U.S.)
      1. Company Snapshot
      2. Company Overview
      3. Financials
      4. Technology Benchmarking
      5. Recent Developments
    4. Eli Lilly and Company (U.S.)
      1. Company Snapshot
      2. Company Overview
      3. Financials
      4. Technology Benchmarking
      5. Recent Developments
    5. Genentech, Inc. (U.S.)
      1. Company Snapshot
      2. Company Overview
      3. Financials
      4. Technology Benchmarking
      5. Recent Developments
    6. GlaxoSmithKline plc (U.K.)
      1. Company Snapshot
      2. Company Overview
      3. Financials
      4. Technology Benchmarking
      5. Recent Developments
    7. Hoffmann-La Roche AG (Switzerland)
      1. Company Snapshot
      2. Company Overview
      3. Financials
      4. Technology Benchmarking
      5. Recent Developments
    8. Merck & Co., Inc. (U.S.)
      1. Company Snapshot
      2. Company Overview
      3. Financials
      4. Technology Benchmarking
      5. Recent Developments
    9. Pfizer, Inc. (U.S.)
      1. Company Snapshot
      2. Company Overview
      3. Financials
      4. Technology Benchmarking
      5. Recent Developments
    10. Ventana Medical Systems, Inc. (U.S.)
      1. Company Snapshot
      2. Company Overview
      3. Financials
      4. Technology Benchmarking
      5. Recent Developments
    11.   Company 11
      1. Company Snapshot
      2. Company Overview
      3. Financials
      4. Technology Benchmarking
      5. Recent Developments
    12. Company 12
      1. Company Snapshot
      2. Company Overview
      3. Financials
      4. Technology Benchmarking
      5. Recent Developments
    13. Company 13
      1. Company Snapshot
      2. Company Overview
      3. Financials
      4. Technology Benchmarking
      5. Recent Developments
    14. Company 14
      1. Company Snapshot
      2. Company Overview
      3. Financials
      4. Technology Benchmarking
      5. Recent Developments
    15. Company 15
      1. Company Snapshot
      2. Company Overview
      3. Financials
      4. Technology Benchmarking
      5. Recent Developments
    16. Others Prominent Players

Conclusion & Recommendations

Select License Type

7 Reasons to Choose EHMR Reports

  • Customer’s Satisfaction

    First and foremost client’s satisfaction, which is very important for Erevna Healthcare and we are committed towards it

  • Client Report

    Customised reports

    Expert in healthcare domain and in depth insights on the report. Erevna Healthcare also customise reports as per the client’s requirement

  • Analyst Support

    Experienced team of analysts with strong background in Pharma, Life Sciences and Biotechnology

  • Assured Quality

    Each report passes through three tiers of quality check

  • Stick to the timeline

    Stick to the timeline

    Erevna Healthcare analysts stick to the timeline

  • Quick delivery

    Quick delivery of reports as per client’s request in three different forms i.e. pdf, ppt and word

  • 24x7 Supprt

    24*7 Support

    24*7 Support post delivery/dispatch of all the reports